Published in Cancer Res on June 15, 2010
Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol (2013) 2.03
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med (2012) 1.68
Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov (2013) 1.66
Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma. Neuro Oncol (2012) 1.21
Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res (2014) 1.12
Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology (2011) 1.07
Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury. Am J Respir Cell Mol Biol (2013) 1.02
Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways. Cell Cycle (2012) 0.96
All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. FEBS J (2015) 0.93
Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia. PLoS One (2012) 0.91
Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. Arthritis Rheum (2011) 0.89
Essential role of protein phosphatase 2A in metaphase II arrest and activation of mouse eggs shown by okadaic acid, dominant negative protein phosphatase 2A, and FTY720. J Biol Chem (2011) 0.89
Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond. Anticancer Agents Med Chem (2011) 0.88
From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies. Front Oncol (2015) 0.87
Targeting sphingosine-1-phosphate in hematologic malignancies. Anticancer Agents Med Chem (2011) 0.85
PP2A: The Wolf in Sheep's Clothing? Cancers (Basel) (2015) 0.85
Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress. Cell Death Dis (2012) 0.83
The Basic Biology of PP2A in Hematologic Cells and Malignancies. Front Oncol (2014) 0.83
SETting OP449 into the PP2A-activating drug family. Clin Cancer Res (2014) 0.82
The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget (2016) 0.82
Fingolimod (FTY720) stimulates Ca(2+)/calcineurin signaling in fission yeast. PLoS One (2013) 0.81
Regulation of PP2A by Sphingolipid Metabolism and Signaling. Front Oncol (2015) 0.81
Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells. Haematologica (2013) 0.80
FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system. Clinics (Sao Paulo) (2013) 0.80
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia. Front Oncol (2016) 0.80
Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors. Mod Pathol (2016) 0.79
The role of translation initiation regulation in haematopoiesis. Comp Funct Genomics (2012) 0.79
Basal protein phosphatase 2A activity restrains cytokine expression: role for MAPKs and tristetraprolin. Sci Rep (2015) 0.78
Chronic myeloid leukemia: the basis of treatment for tomorrow. Haematologica (2011) 0.78
The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod. J Cell Mol Med (2015) 0.78
Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia. Front Oncol (2015) 0.77
A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia. Anticancer Drugs (2016) 0.76
The phosphorylated form of FTY720 activates PP2A, represses inflammation and is devoid of S1P agonism in A549 lung epithelial cells. Sci Rep (2016) 0.76
Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers -- Letter. Cancer Res (2011) 0.76
Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia. Oncotarget (2016) 0.75
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget (2016) 0.75
Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest. Oncotarget (2016) 0.75
Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma. Cancer Biol Ther (2015) 0.75
Where are we going with CML research? Leuk Suppl (2012) 0.75
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (1998) 21.13
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature (2004) 12.72
Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer (1980) 10.11
Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J (2001) 9.40
Growth of factor-dependent hemopoietic precursor cell lines. J Exp Med (1980) 5.80
"Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev (2008) 3.80
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest (1993) 3.57
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell (2005) 3.44
Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell (2004) 3.29
An improved procedure for identifying and quantitating protein phosphatases in mammalian tissues. FEBS Lett (1989) 3.10
PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci (2008) 3.04
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest (2007) 2.91
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol (2006) 2.87
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther (2002) 2.68
The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol (1999) 2.57
BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet (2001) 2.46
Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood (1991) 2.33
Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene (2000) 2.08
Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol (1999) 1.95
Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood (1987) 1.77
Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells (2005) 1.76
Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. J Natl Cancer Inst (2006) 1.76
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2007) 1.69
Imatinib for systemic mast-cell disease. Lancet (2003) 1.62
Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res (2009) 1.57
Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res (2005) 1.52
A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol (2003) 1.48
SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol Cell Biol (1998) 1.41
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res (2008) 1.39
KIT mutations are common in testicular seminomas. Am J Pathol (2004) 1.36
Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res (2010) 1.22
Signal transduction by several KIT juxtamembrane domain mutations. Oncogene (2003) 1.20
Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut (2000) 1.19
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol (2008) 1.14
Reduced expression of the Aalpha subunit of protein phosphatase 2A in human gliomas in the absence of mutations in the Aalpha and Abeta subunit genes. Int J Cancer (2001) 1.06
Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer (1998) 1.05
Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B. Eur J Cancer (2007) 1.05
Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther (2007) 1.03
Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother (2007) 0.97
Reduced expression of the regulatory A subunit of serine/threonine protein phosphatase 2A in human breast cancer MCF-7 cells. Int J Oncol (2003) 0.91
Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Int J Cancer (2003) 0.90
Mast cell function: regulation of degranulation by serine/threonine phosphatases. Pharmacol Ther (2006) 0.90
A truncated isoform of the protein phosphatase 2A B56gamma regulatory subunit may promote genetic instability and cause tumor progression. Am J Pathol (2003) 0.87
Developmental regulation of protein phosphatase types 1 and 2A in post-hatch chicken brain. Neurochem Res (1998) 0.84
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study. Haematologica (2007) 0.79
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A (2012) 5.07
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell (2010) 4.07
The biology of CML blast crisis. Blood (2004) 3.59
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell (2005) 3.44
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest (2007) 2.91
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol (2006) 2.87
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther (2002) 2.68
Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell (2009) 2.60
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol (2005) 2.41
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell (2010) 2.37
Genome sequence of an Australian kangaroo, Macropus eugenii, provides insight into the evolution of mammalian reproduction and development. Genome Biol (2011) 2.18
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood (2013) 2.16
BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell (2003) 2.08
Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol (2013) 2.03
Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell (2012) 2.01
Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol (2010) 1.98
Safety of brain 3-T MR imaging with transmit-receive head coil in patients with cardiac pacemakers: pilot prospective study with 51 examinations. Radiology (2008) 1.91
Magnetic resonance imaging at 1.5-T in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol (2009) 1.87
Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood (2007) 1.83
First-pass and steady-state MR angiography of thoracic vasculature in children and adolescents. JACC Cardiovasc Imaging (2010) 1.74
Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell (2007) 1.72
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72
Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J (2004) 1.71
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2007) 1.69
Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res (2005) 1.69
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med (2012) 1.68
A supramolecular assembly formed by influenza A virus genomic RNA segments. Nucleic Acids Res (2011) 1.65
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell (2010) 1.64
The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood (2009) 1.63
Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. Nucleic Acids Res (2007) 1.62
The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells. Blood (2010) 1.60
Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol (2004) 1.57
Low-field magnetic resonance imaging: increased safety for pacemaker patients? Europace (2010) 1.57
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood (2005) 1.56
A novel dysfunctional growth hormone variant (Ile179Met) exhibits a decreased ability to activate the extracellular signal-regulated kinase pathway. J Clin Endocrinol Metab (2004) 1.55
Dual-source parallel radiofrequency excitation body MR imaging compared with standard MR imaging at 3.0 T: initial clinical experience. Radiology (2010) 1.54
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood (2012) 1.51
alpha3beta1 integrin-CD151, a component of the cadherin-catenin complex, regulates PTPmu expression and cell-cell adhesion. J Cell Biol (2003) 1.49
A critical role for tetraspanin CD151 in alpha3beta1 and alpha6beta4 integrin-dependent tumor cell functions on laminin-5. Mol Biol Cell (2006) 1.47
Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Control Release (2006) 1.45
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem (2002) 1.44
Cognitive trajectory after transcatheter aortic valve implantation. Circ Cardiovasc Interv (2013) 1.44
TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol (2008) 1.43
Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem (2003) 1.43
Apo-Hsp90 coexists in two open conformational states in solution. Biol Cell (2008) 1.39
hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Mol Cell Biol (2002) 1.39
Feasibility of outpatient coronary angiography with "ad hoc" angioplasty. Arch Cardiovasc Dis (2008) 1.38
Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev (2008) 1.37
Deletion of CD151 results in a strain-dependent glomerular disease due to severe alterations of the glomerular basement membrane. Am J Pathol (2008) 1.36
Precancerous stem cells have the potential for both benign and malignant differentiation. PLoS One (2007) 1.36
Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation. Blood (2003) 1.35
Regulation of acute graft-versus-host disease by microRNA-155. Blood (2012) 1.35
Identification of ANKRD11 as a p53 coactivator. J Cell Sci (2008) 1.33
Safety, feasibility, and diagnostic value of cardiac magnetic resonance imaging in patients with cardiac pacemakers and implantable cardioverters/defibrillators at 1.5 T. Am Heart J (2011) 1.30
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res (2013) 1.30
Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A (2005) 1.28
Evolutionary divergence of enzymatic mechanisms for posttranslational polyglycylation. Cell (2009) 1.28
Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clin Cancer Res (2005) 1.27
Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. J Cell Sci (2013) 1.24
Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet (2013) 1.24
CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3. Cancer Res (2002) 1.24
Wound healing is defective in mice lacking tetraspanin CD151. J Invest Dermatol (2006) 1.22
Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J Immunol (2008) 1.21
The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity. Nat Med (2013) 1.20
CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator? Cancer Epidemiol Biomarkers Prev (2004) 1.19
High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood (2007) 1.19
Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood (2006) 1.19
Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood (2011) 1.19
Silver impairs neurodevelopment: studies in PC12 cells. Environ Health Perspect (2010) 1.18
Tissue-specific tropomyosin isoform composition. J Histochem Cytochem (2005) 1.17
The PP2A inhibitor SET regulates natural killer cell IFN-gamma production. J Exp Med (2007) 1.15
The inner mitochondrial membrane has aquaporin-8 water channels and is highly permeable to water. J Biol Chem (2005) 1.15
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood (2013) 1.14
The tetraspanin superfamily member CD151 regulates outside-in integrin alphaIIbbeta3 signaling and platelet function. Blood (2004) 1.14
Evaluation of cumulative effects of MR imaging on pacemaker systems at 1.5 Tesla. Pacing Clin Electrophysiol (2009) 1.13
Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors. Hum Mutat (2004) 1.13
Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO J (2006) 1.12
From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin Cancer Res (2007) 1.11
Quantitative imaging of myocardial infarct in rats with high resolution pinhole SPECT. Int J Cardiovasc Imaging (2006) 1.10
An in vitro network of intermolecular interactions between viral RNA segments of an avian H5N2 influenza A virus: comparison with a human H3N2 virus. Nucleic Acids Res (2012) 1.10
n-6 Fatty acids and cardiovascular health: a review of the evidence for dietary intake recommendations. Br J Nutr (2010) 1.09